Alkermes plc

Alkermes PLC is a fully-integrated biopharmaceutical company with international operations. The company researches, develops, and manufactures medicines to treat debilitating diseases such as those in the fields of oncology and neuroscience. Established in 1987, Alkermes is based in Dublin, Ireland. Available on the NASDAQ GS stock exchange, the company is listed using the ALKS ticker. As of November 2020, this stock provided a -10.06% one-year return. The ALKS share price ranged from a 52-week high of $21.86 in December 2019 before falling to a 52-week low of $11.98 in March 2020. In November 2020, this stock was trading at $18.50. Alkermes has numerous product candidates in development, including those to treat cancer, neurodegenerative disorders, schizophrenia, and bipolar I disorder. Additionally, the company has several products that are already on the market, including Aristada to treat schizophrenia, Vivitrol to treat alcohol and opioid dependence, Risperdal Consta to treat schizophrenia and bipolar I disorder, and a number of other medications. Alkermes has a collaboration agreement with Janssen Pharmaceutica, a license agreement with Acorda Therapeutics, Inc., and both types of agreements with Biogen Swiss Manufacturing GmbH. Make ALKS stock an addition to your eToro watchlist to start receiving the latest news and updates.